$1.18 Billion in Sales Expected for Diplomat Pharmacy Inc (NYSE:DPLO) This Quarter

Brokerages expect that Diplomat Pharmacy Inc (NYSE:DPLO) will announce $1.18 billion in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Diplomat Pharmacy’s earnings. The highest sales estimate is $1.23 billion and the lowest is $1.16 billion. Diplomat Pharmacy posted sales of $1.37 billion in the same quarter last year, which would indicate a negative year over year growth rate of 13.9%. The firm is scheduled to report its next earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Diplomat Pharmacy will report full year sales of $4.86 billion for the current financial year, with estimates ranging from $4.82 billion to $4.87 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $4.98 billion, with estimates ranging from $4.86 billion to $5.14 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Friday, August 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. Diplomat Pharmacy’s revenue was down 9.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) EPS.

DPLO has been the topic of several recent analyst reports. ValuEngine raised shares of Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. Wells Fargo & Co raised their price target on shares of Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a “market perform” rating in a research note on Tuesday, August 13th. Credit Suisse Group reduced their price target on shares of Diplomat Pharmacy from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Monday, April 29th. Finally, Barclays set a $7.00 price target on shares of Diplomat Pharmacy and gave the stock a “buy” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.85.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in shares of Diplomat Pharmacy by 13.4% in the fourth quarter. Geode Capital Management LLC now owns 598,753 shares of the company’s stock valued at $8,059,000 after acquiring an additional 70,528 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Diplomat Pharmacy by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,128,358 shares of the company’s stock valued at $28,650,000 after acquiring an additional 395,246 shares during the period. Norges Bank purchased a new position in shares of Diplomat Pharmacy in the fourth quarter valued at about $2,592,000. BNP Paribas Arbitrage SA increased its position in shares of Diplomat Pharmacy by 446.9% in the first quarter. BNP Paribas Arbitrage SA now owns 13,104 shares of the company’s stock valued at $76,000 after acquiring an additional 10,708 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Diplomat Pharmacy in the first quarter valued at about $118,000. 87.92% of the stock is currently owned by institutional investors and hedge funds.

DPLO stock traded up $0.02 during trading on Thursday, hitting $5.74. The company had a trading volume of 850,400 shares, compared to its average volume of 1,034,862. The firm has a market capitalization of $432.99 million, a P/E ratio of 28.70 and a beta of 1.06. Diplomat Pharmacy has a 52-week low of $4.17 and a 52-week high of $21.48. The company has a 50 day simple moving average of $5.51 and a 200-day simple moving average of $6.36. The company has a quick ratio of 0.66, a current ratio of 0.99 and a debt-to-equity ratio of 1.53.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: What are the benefits of momentum investing?

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.